Molecular targeting of carbonic anhydrase ix in mice with hypoxic HT29 colorectal tumor xenografts

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Carlin, Sean ^a   Khan, Nahida ^a   Ku, Thomas ^a   Longo, Valerie A ^a   Larson, Steve M ^a   Smith Jones, Peter M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CARBONATE DEHYDRATASE IX; DIAGNOSTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; INDIUM 111; MONOCLONAL ANTIBODY G250; TUMOR MARKER; CARBONATE DEHYDRATASE; CARBONIC ANHYDRASE IX, MOUSE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BINDING AFFINITY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ENZYME ANALYSIS; EX VIVO STUDY; HYPOXIA; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; ISOTOPE LABELING; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOACTIVITY; SENSITIVITY AND SPECIFICITY; TISSUE PERFUSION; TUMOR BLOOD FLOW; TUMOR XENOGRAFT; ANIMAL; CELL HYPOXIA; CELL STRAIN HT29; COLORECTAL TUMOR; DRUG SCREENING; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; NUDE MOUSE; PATHOLOGY; VASCULARIZATION;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; CARBONIC ANHYDRASES; CELL HYPOXIA; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; MOLECULAR IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956283843     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010857     Document Type: Article

References (37)

1. Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3: 164-167.
2. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, et al. (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802-811.
3. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, et al. (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19: 3660-3668.
4. Hussain SA, Palmer DH, Ganesan R, Hiller L, Gregory J, et al. (2004) Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep 11: 1005-1010.
5. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, et al. (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24: 727-735.
6. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, et al. (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399.
7. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, et al. (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21: 473-482.
8. Kivela AJ, Kivela J, Saarnio J, Parkkila S (2005) Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. World J Gastroenterol 11: 155-163.
9. Saarnio J, Parkkila S, Parkkila AK, Pastorekova S, Haukipuro K, et al. (2001) Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J Hepatol 35: 643-649.
10. Korkeila E, Talvinen K, Jaakkola PM, Minn H, Syrjanen K, et al. (2009) Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 100: 874-880.
11. Pastorekova S, Parkkila S, Parkkila AK, Opavsky R, Zelnik V, et al. (1997) Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 112: 398-408.
12. Wouters A, Pauwels B, Lardon F, Vermorken JB (2007) Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 12: 690-712.
13. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
14. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, et al. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083.
15. Li XF, Carlin S, Urano M, Russell J, Ling CC, et al. (2007) Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 67: 7646-7653.
16. He F, Deng X, Wen B, Liu Y, Sun X, et al. (2008) Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. Cancer Res 68: 8597-8606.
17. Jarvela S, Parkkila S, Bragge H, Kahkonen M, Parkkila AK, et al. (2008) Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 8: 1.
18. Grabmaier K, MC AdW, Verhaegh GW, Schalken JA, Oosterwijk E (2004) Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23: 5624-5631.
19. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA (2003) Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9: 4641-4652.
20. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, et al. (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8: 304-310.
21. Lawrentschuk N, Lee FT, Jones G, Rigopoulos A, Mountain A, et al. (2009) Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT. Urol Oncol.
22. Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, et al. (2006) Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243: 334-340.
23. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, et al. (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61: 7992-7998.
24. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, et al. (2001) Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascular-ization and resistance of squamous cell head and neck cancer to chemor-adiotherapy. Clin Cancer Res 7: 3399-3403.
25. Said HM, Hagemann C, Staab A, Stojic J, Kuhnel S, et al. (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 83: 398-405.
26. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95-109.
27. Buchegger F, Haskell CM, Schreyer M, Scazziga BR, Randin S, et al. (1983) Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med 158: 413-427.
28. Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-3408.
29. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, et al. (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 52: 5144-5153.
30. Fujimori K, Covell DG, Fletcher JE, Weinstein JN (1989) Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res 49: 5656-5663.
31. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8: 2861-2871.
32. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, et al. (1998) Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 42: 225-241.
33. Chrastina A, Zavada J, Parkkila S, Kaluz S, Kaluzova M, et al. (2003) Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 105: 873-881.
34. Smith-Jones PM, Solit DB (2004) Generation of DOTA-conjugated antibody fragments for radioimmunoimaging. Methods Enzymol 386: 262-275.
35. Fraker PJ, Speck JC, Jr. (1978) Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 80: 849-857.
36. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77-89.
37. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, et al. (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60: 5237-5243.